Filing Details
- Accession Number:
- 0001209191-23-002975
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-11 16:06:43
- Reporting Period:
- 2023-01-10
- Accepted Time:
- 2023-01-11 16:06:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821530 | Iii J Edward Dulac | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-01-10 | 7,331 | $5.24 | 129,470 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
Billionaire Hedge Funds
